According to Zhitong Finance APP, Tesla (TSLA.US) CEO Elon Musk emphasized in a post on X platform on Wednesday that he prefers Eli Lilly and Co (LLY.US)'s competitor Mounjaro over Novo-Nordisk A/S (NVO.US)'s weight loss treatment Ozempic.

On Wednesday, Musk published a post titled "Ozempic Santa" along with a picture of himself dressed as Santa Claus. When asked about the specific product he is using, Musk noted, "Technically, it's Mounjaro, but that sounds different."

"Mounjaro seems to have fewer side effects and to be more effective," he explained.

It is understood that Mounjaro and Ozempic's generic names are tirzepatide and semaglutide, respectively, and they belong to a class of glucagon-like peptide-1 (GLP-1) receptor agonists, marketed under the brand names Zepbond and Wegovy for weight loss.

Musk has previously credited his weight loss to Wegovy. However, given Musk's firm support for GLP-1, he seems at odds with USA's incoming president Trump's pick for Health Secretary, Robert F. Kennedy, who has long argued for dietary control rather than relying on drugs to combat obesity.